

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## CLARITY MEDICAL GROUP HOLDING LIMITED

清晰醫療集團控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1406)**

### **(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF AUDIT COMMITTEE;**

**AND**

### **(2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

#### **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF AUDIT COMMITTEE**

The board (the “**Board**”) of directors (the “**Directors**”) of Clarity Medical Group Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Xu Anliang (“**Mr. Xu**”) has been appointed as an independent non-executive Director (“**INED**”) and a member of the audit committee of the Company by the Board, with effect from 22 January 2026.

Mr. Xu will enter into a letter of appointment with the Company for a term of 3 years commencing from the date of appointment, which may be terminated by not less than three calendar months’ notice in writing or payment in lieu of notice served by either party on the other. Mr. Xu is entitled to receive a fixed director’s remuneration of HK\$300,000 per annum, which was recommended by the remuneration committee of the Company (the “**Remuneration Committee**”) and determined by the Board, with reference to his responsibilities, experience and market rate of directors’ remuneration of companies listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) that are of a comparable size and operation as the Company.

The biographical details of Mr. Xu required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) are set out below:

Mr. Xu, aged 62, holds a master’s degree and obtained a doctor’s degree in economics from Nankai University in 2006. Mr. Xu is also a non-practicing member of the Chinese Institute of Certified Public Accountants.

Mr. Xu has been working for government institutions and corporations for many years. From 2019 to 2024, Mr. Xu served as a senior executive vice president of Wanxiang Group Corporation (“**Wanxiang Group**”), the chairman of Wanxiang Venture Capital Co., Ltd, and held various positions in the subsidiaries of Wanxiang Group. Mr. Xu served as an executive director of Puxing Energy Limited, a company listed on the Main Board of the Stock Exchange (stock code: 0090), from April 2021 to March 2024.

To the best of the Directors’ information, knowledge and belief, having made all reasonable enquiries, save as disclosed above, Mr. Xu (i) did not hold any other directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas during the last three years; (ii) does not have any other major appointments and professional qualifications; and (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder (as defined under the Listing Rules) of the Company.

As at the date of this announcement, Mr. Xu (i) does not have, and is not deemed to have any interests or short positions in any shares or underlying shares and debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (ii) does not have any other positions held within the Company or other members of the Group.

Save as disclosed above, and as far as the Board is aware, there is no other information that needs to be disclosed in accordance with Rule 13.51(2) of the Listing Rules concerning the appointment of Mr. Xu, and there are no other matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

Mr. Xu has confirmed that (i) he is independent with regard to each of the criteria set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Group or any connection with any core connected persons (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

The Board would like to extend a warm welcome to Mr. Xu on joining the Board.

## **APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The Board announces that Mr. Sun Peng (“**Mr. Sun**”) has been appointed as a non-executive Director (“**NED**”) by the Board, with effect from 22 January 2026.

Mr. Sun will enter into a letter of appointment with the Company for a term of 3 years commencing from the date of appointment, which may be terminated by not less than three calendar months’ notice in writing or payment in lieu of notice served by either party on the other. Mr. Sun is entitled to receive a fixed director’s remuneration of HK\$300,000 per annum, which was recommended by the Remuneration Committee and determined by the Board, with reference to his responsibilities, experience and market rate of directors’ remuneration of companies listed on the Stock Exchange that are of a comparable size and operation as the Company.

The biographical details of Mr. Sun required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules are set out below:

Mr. Sun, aged 48, has over 20 years of experience in software engineering. He obtained a bachelor's degree in Engineering in Computer Science and a master's degree in Computer Science from the University of Science and Technology of China in 2002 and 2005 respectively.

From July 2005 to May 2010, he worked as a software engineer at the Microsoft Advanced Technology Centre in Beijing. From May 2010 to January 2022, he worked at Xiaomi Corporation as a software engineer. Since February 2022, he has been a software engineer at Hefei Whale Microelectronics Co., Ltd., a wholly-owned subsidiary of Jiangsu Yitong High-tech Co., Ltd. ("**Yitong**"), the shares of which are listed on the Shenzhen Stock Exchange (stock code: 300211). He is also the general manager and director of Yitong, since February 2022 and April 2023 respectively.

To the best of the Directors' information, knowledge and belief, having made all reasonable enquiries, save as disclosed above, Mr. Sun (i) did not hold any other directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas during the last three years; (ii) does not have any other major appointments and professional qualifications; and (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder (as defined under the Listing Rules) of the Company.

As at the date of this announcement, Mr. Sun (i) does not have, and is not deemed to have any interests or short positions in any shares or underlying shares and debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (ii) does not have any other positions held within the Company or other members of the Group.

Save as disclosed above, and as far as the Board is aware, there is no other information that needs to be disclosed in accordance with Rule 13.51(2) of the Listing Rules concerning the appointment of Mr. Sun, and there are no other matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to extend a warm welcome to Mr. Sun on joining the Board.

By order of the Board  
**CLARITY MEDICAL GROUP HOLDING LIMITED**  
**JIANG Bo**  
*Executive Director and Chief Executive Officer*

Hong Kong, 22 January 2026

*As at the date of this announcement, the Board comprises Mr. JIANG Bo as executive Director, Mr. CHEN Jiarong, Professor WANG Qinmei and Mr. SUN Peng as non-executive Directors, and Mr. WANG Can, Ms. CI Ying, Dr. CHEN Poujian and Mr. XU Anliang as independent non-executive Directors.*